`
`Case 1:23-cv-00089-TSK Document 59-1 Filed 01/08/24 Page 1 of 2 PageID #: 3848
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit A
`
`
`
`1
`
`
`
`
`
`Case 1:23-cv-00089-TSK Document 59-1 Filed 01/08/24 Page 2 of 2 PageID #: 3849
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`
`REGENERON PHARMACEUTICALS, INC.,
`
`Plaintiff,
`
`v.
`
`
`CELLTRION, INC.,
`Defendant.
`
`Civil Action No. 1:23-cv-89-TSK
`
`PROPOSED SCHEDULE
`
`Event
`
`Deadline
`
`Celltrion deadline to answer or otherwise
`respond to the Complaint, e.g., by filing a
`motion for lack of personal jurisdiction and/or
`improper venue (“MTD”)
`
`Regeneron to file motion for preliminary
`injunction against Celltrion, identifying no
`more than 3 patents and 8 claims (“MPI”)
`
`Celltrion deadline to request targeted discovery
`
`Regeneron to file opposition to any MTD
`
`Regeneron completes responses and production
`to targeted discovery requests
`
`Celltrion to file reply to MTD
`
`Celltrion to file response to MPI
`
`Regeneron to file reply to MPI
`
`Celltrion to file surreply to MPI
`
`Proposed hearing on MPI
`
`In-person status conference with lead counsel
`ahead of May 18, 2024 expiration of regulatory
`exclusivity
`
`January 17, 2024
`
`January 17, 2024
`
`January 24, 2024
`
`January 31, 2024
`
`January 31, 2024
`
`February 7, 2024
`
`March 7, 2024
`
`April 8, 2024
`
`April 25, 2024
`
`_________________ [week of April 29, 2024]
`
`May 13, 2024
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`